Molecular structure of (S)-Lansoprazole, CAS Number: 138530-95-7
(S)-Lansoprazole (CAS 138530-95-7)
See product citations (2)
Alternate Names:
2-[(S)-[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole
Application:
(S)-Lansoprazole is a gastric proton pump inhibitor
CAS Number:
138530-95-7
Molecular Weight:
369.36
Molecular Formula:
C16H14F3N3O2S
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
The S-enantiomer of lansoprazole that acts as a gastric proton pump inhibitor and antiulcerative.
(S)-Lansoprazole (CAS 138530-95-7) References
- Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders. | Figgitt, DP. and McClellan, KJ. 2000. Drugs. 60: 925-54. PMID: 11085201
- Role of CYP3A4 and CYP2C19 in the stereoselective metabolism of lansoprazole by human liver microsomes. | Katsuki, H., et al. 2001. Eur J Clin Pharmacol. 57: 709-15. PMID: 11829200
- Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19. | Kim, KA., et al. 2002. Clin Pharmacol Ther. 72: 90-9. PMID: 12152007
- Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. | Barradell, LB., et al. 1992. Drugs. 44: 225-50. PMID: 1382017
- Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes. | Miura, M., et al. 2004. Eur J Clin Pharmacol. 60: 623-8. PMID: 15448955
- Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine. | Miura, M., et al. 2005. Br J Clin Pharmacol. 60: 61-8. PMID: 15963095
- Enantioselective disposition of lansoprazole and rabeprazole in human plasma. | Miura, M. 2006. Yakugaku Zasshi. 126: 395-402. PMID: 16755125
- Correlation between R/S enantiomer ratio of lansoprazole and CYP2C19 activity after single oral and enteral administration. | Miura, M., et al. 2010. Chirality. 22: 635-40. PMID: 20014035
- Determination of S-(-)-lansoprazole in dexlansoprazole preparation by capillary zone electrophoresis. | Chung, HK., et al. 2017. Arch Pharm Res. 40: 962-971. PMID: 28766240
- Stereoselective Inhibition of Renal Basolateral Human Organic Anion Transporter 3 by Lansoprazole Enantiomers. | Hamada, Y., et al. 2018. Pharmacology. 101: 176-183. PMID: 29353278
Inhibitor of:
SPP.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
(S)-Lansoprazole, 1 mg | sc-208369 | 1 mg | $360.00 |